Tested medicine nabilone for agitation in Alzheimer’s dementia
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This Phase 3 trial studies whether nabilone can reduce agitation (restlessness, anger, or difficult behavior) in people with Alzheimer’s dementia. It’s designed for older adults who already have agitation despite standard dementia care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 55 or older (and if you are female, you’re post-menopausal)
- A clinician has diagnosed you with dementia due to Alzheimer’s disease (or a mix of causes including Alzheimer’s)
- Your memory/thinking test score (sMMSE) is 24 or lower
- You currently have agitation that is considered clinically significant
- If you take dementia brain medications like donepezil, rivastigmine, galantamine, or memantine, your dose must be stable for 3 months
- A primary caregiver must join study visits and be able to do the study questions in English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a CBD medication can help reduce agitation in people with Alzheimer's disease. It's for adults 55 and older who have significant agitation and mild to moderate dementia.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Hear when a new Agitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.